A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)

Inclusion Criteria: * females of infertile couples for whom COS and IVF or ICSI is indicated * body mass index between 18 and 29 kg/m2 * willing and able to give written informed consent. Exclusion Criteria: * More than three previous COS cycles for assisted reproduction since last established ongoing pregnancy (if applicable) * History of no or low ovarian response to FSH/human menopausal gonadotropin (hMG) treatment * Less than 2 ovaries or any other ovarian abnormality including endometrioma * Presence of unilateral or bilateral hydrosalpinx * Any ovarian and/or abdominal abnormality that would interfere with adequate ultrasound investigation of at least one ovary * History of or current polycystic ovary syndrome (PCOS) * History of/or current endocrine abnormality * Any clinically relevant hormone value outside the reference range during the early follicular phase * Any clinically significant abnormal laboratory value * Hypertension or currently treated hypertension * Recent history of current epilepsy, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary disease * Alcohol or drug abuse, or history thereof * Current serious allergic symptoms * Abnormal cervical smear * Known hypersensitivity to gonadotropin releasing hormone (GnRH) or its analogs; * Contra-indications for the use of gonadotropins * Use of hormonal preparations within 1 month prior to the date of signing consent; * Administration of any investigational product within 3 months prior to screening.